富祥药业(300497.SZ)发布上半年业绩，归母净亏损691.12万元，收窄69.23%

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) reported a decline in revenue for the first half of 2025, indicating challenges in its financial performance while showing improvements in net losses compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 515 million yuan, representing a year-on-year decrease of 24.58% [1] - The net loss attributable to shareholders of the listed company was 6.9112 million yuan, which narrowed by 69.23% year-on-year [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 32.1798 million yuan, a reduction of 34.91% compared to the previous year [1] - The basic loss per share was 0.01 yuan [1]